雷奈酸锶对糖皮质激素诱导骨质疏松大鼠骨形态计量学的研究

被引:8
作者
孙平 [1 ]
王晓东 [1 ]
洪曼杰 [1 ]
邓伟民 [2 ]
蔡德鸿 [3 ]
机构
[1] 广东药学院附属第一医院骨科
[2] 广州陆军总医院中医科
[3] 南方医科大学附属珠江医院
关键词
雷奈酸锶; 骨密度; 骨形态计量学; 糖皮质激素; 大鼠;
D O I
暂无
中图分类号
R580 []; R595.3 [药源性疾病];
学科分类号
100201 [内科学];
摘要
目的观察雷奈酸锶对糖皮质激素诱导骨质疏松大鼠骨形态计量学的影响。方法 24只3.5月龄SPF级雄性SD大鼠适应性喂养1w后,随机等分为3组:Nrm组:正常对照组;Met组:皮下注射甲强龙(Met)5 mg/(kg.d),每周5次;SrR组:在Met组基础上给予雷奈酸锶900 mg/(kg.d)灌胃。实验期9w。第5腰椎(L5)和右侧股骨用于骨密度测定,右侧胫骨行骨形态计量学分析。结果 Met组L5和股骨BMD显著低于Nrm组;SrR组L5和股骨BMD显著高于Met组。Met组BV/TV,Tb.Th,Tb.N,%Ct.Ar显著低于Nrm组,Tb.Sp,%Ma.Ar,ES/BS显著高于Nrm组;SrR组BV/TV,Tb.Th,Tb.N,%Ct.Ar显著高于Met组;Tb.Sp,ES/BS显著低于Met组。结论给予大鼠SrR 900 mg/(kg.d)灌胃,在提高激素诱导骨质疏松大鼠的骨密度,促进骨形成,降低骨吸收,延缓骨量丢失方面有积极作用;对继发性骨质疏松的预防和治疗有一定前景。
引用
收藏
页码:102 / 105
页数:4
相关论文
共 8 条
[1]
Glucocorticoid-induced osteoporosis: hope on the HORIZON [J].
Gennari, Luigi ;
Bilezikian, John P. .
LANCET, 2009, 373 (9671) :1225-1226
[2]
Prevention of glucocorticoid-induced osteoporosis [J].
van Brussel, M. S. ;
Bultink, I. E. M. ;
Lems, W. F. .
EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (06) :997-1005
[3]
Glucocorticoid-induced osteoporosis [J].
Silverman S.L. ;
Lane N.E. .
Current Osteoporosis Reports, 2009, 7 (1) :23-26
[4]
Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants [J].
Bain, S. D. ;
Jerome, C. ;
Shen, V. ;
Dupin-Roger, I. ;
Ammann, P. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (08) :1417-1428
[5]
Effect of strontium ranelate on fracture healing in rat tibia [J].
Cebesoy, Oguz ;
Tutar, Ediz ;
Kose, Kamil Cagri ;
Baltaci, Yasemin ;
Bagci, Cahit .
JOINT BONE SPINE, 2007, 74 (06) :590-593
[6]
Strontium ranelate: a new treatment for postmenopausal osteoporosis with a dual mode of action. [J].
Reginster J.Y. ;
Sarlet N. ;
Lejeune E. ;
Leonori L. .
Current Osteoporosis Reports, 2005, 3 (1) :30-34
[7]
The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis [J].
van Staa, TP ;
Leufkens, HGM ;
Cooper, C .
OSTEOPOROSIS INTERNATIONAL, 2002, 13 (10) :777-787
[8]
Glucocorticoid-induced osteoporosis in the rat is prevented by the tyrosine phosphatase inhibitor, sodium orthovanadate [J].
Hulley, PA ;
Conradie, MM ;
Langeveldt, CR ;
Hough, FS .
BONE, 2002, 31 (01) :220-229